Posters and Presentations :: SCYNEXIS, Inc. (SCYX)

Ibrexafungerp (SCY-078): A First-in-Class, Orally-Bioavailable, Glucan Synthase Inhibitor has Fungicidal Activity Against <em>C. auris</em>, an Emerging Multidrug-Resistant Pathogen

Ibrexafungerp (SCY-078): A First-in-Class, Orally-Bioavailable, Glucan Synthase Inhibitor has Fungicidal Activity Against C. auris, an Emerging Multidrug-Resistant Pathogen

Stephen Barat, Katyna Borroto-Esoda, David Angulo
MSGERC 2018
September 2018

Ibrexafungerp (formerly SCY-078) Displays Potent <em>In Vitro</em> Activity Against <em>C. glabrata</em> Isolates with Mutations in <em>fks</em> Genes

Ibrexafungerp (formerly SCY-078) Displays Potent In Vitro Activity Against C. glabrata Isolates with Mutations in fks Genes

Stephen Barat, Katyna Borroto-Esoda, David Angulo
ESCMID ASM 2018
September 2018

Ibrexafungerp (formerly SCY-078), a Novel IV/Oral Triterpenoid Antifungal Treatment, is Not Embryo/Feto-toxic

Christina M. Carruthers, Stephen Barat, Porsha Thomas, Elias Lewis
IDSOG 2018
August 2018

SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against <em>Candida</em>, <em>Aspergillus</em> and <em>Pneumocystis</em> spp.

SCY-078: A first-in-class, orally-bioavailable, glucan synthase inhibitor has broad spectrum activity against Candida, Aspergillus and Pneumocystis spp.

Stephen Barat, Katyna Borroto-Esoda, David Angulo
ISHAM 2018
June 2018

SCY-078, a Novel IV/Oral Triterpenoid Antifungal Treatment, is Not Embryo/Feto-toxic

Christina M. Carruthers, Stephen Barat, Porsha Thomas, Elise Lewis
Teratology 2018
June 2018

SCY-078: A First-in-class, Orally-bioavailable, Glucan Synthase Inhibitor has Activity Alone and is Synergistic with Azole Antifungal Agents against Aspergillus spp.

S. Barat, K. Borroto-Esoda, L. Long, E. Larkin, R Sherif, F Zohra Abidi, M. Ghannoum, R. Petraitiene, V. Petraitis, T. Walsh, D. Angulo
ICHS 2018
June 2018

Morphological Effect of SCY-078 and Caspofungin on Different Caspofungin-Resistant <em>Candida</em> Species

Morphological Effect of SCY-078 and Caspofungin on Different Caspofungin-Resistant Candida Species

C. Hager, P. Lun Sun, H. Fujioka, F. Abidi, N. Avishai, A. Avishai, K. Borroto-Esoda, S. Barat, D. Angulo, M. Ghannoum
ASM Microbe 2018
June 2018

Does Sabouraud Dextrose Broth, Compared to RPMI, Differentiate Susceptibility Between Resistant and Susceptible <em>C. glabrata</em> and <em>C. albicans</em> Isolates to SCY-078, a Novel β-D-glucan Synthase Inhibitor, and Caspofungin?

Does Sabouraud Dextrose Broth, Compared to RPMI, Differentiate Susceptibility Between Resistant and Susceptible C. glabrata and C. albicans Isolates to SCY-078, a Novel β-D-glucan Synthase Inhibitor, and Caspofungin?

L. Long, E. Larkin, R. Sherif, F. Abidi, S. Vasavada, K. Borroto-Esoda, S. Barat, D. Angulo, N. Wiederhold, M. Ghannoum
ASM Microbe 2018
June 2018

<em>In vitro</em> Activity of SCY-078 in Combination with Isavuconazole or Amphotericin B against Medically Important Moulds

In vitro Activity of SCY-078 in Combination with Isavuconazole or Amphotericin B against Medically Important Moulds

V. Petraitis, P. Kavaliauskas, R. Planciuniene, M.Viragailis, R.Petraitiene, S.Barat, K. Borroto-Esoada, D. Angulo, T. Walsh
ASM Microbe 2018
June 2018

<em>Candida auris</em>, A Difficult to Treat, Emerging Pathogen

Candida auris, A Difficult to Treat, Emerging Pathogen

S. Barat
Superbugs and Superdrugs 2018
March 2018